Blood clotting activity and clot risk in women using hormonal contraceptives
Compares blood clotting measures in women using hormonal contraceptives and women not using them.
Key facts
- Who runs it
- University Of Debrecen
- Where
- Hungary1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Evaluation of Thrombin Generation and Thrombosis Risk in Women on Hormonal Contraceptives with a Focus on Modifiable Risk Factors
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 350 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Jul 2029
- Type of study
- Interventional
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who use hormonal birth control (HC), and healthy women who do not, to study blood clotting and clot risk.
- Age
- 18-40 years in the criteria (the record's age field says 18 to 64 years).
- Sex
- Women only.
- Earlier treatment
- Users must have used hormonal contraceptives for at least 3 months. The comparison group must not have used them for at least 3 months.
Main reasons for not taking part
- Past blood clots in veins or arteries, unexplained bleeding or hemophilia
- Use of blood thinners or antiplatelet drugs, including NSAIDs, in the past 10 days
- Pregnancy or breastfeeding
- Cancer in the past 5 years, or autoimmune disease that affects clot risk
- Acute inflammation or infection, chronic kidney or liver disease, or major surgery in the past 3 months
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Women aged 18-40 years
- Current user of HC for at least 3 months/ Healthy non-users of HCs for at least 3 months as a control group
- Signed informed consent
Who cannot take part
- Major surgery within the past 3 months
- History of venous/arterial thromboembolic disorders
- History of unexplained bleeding or hemophilia
- Malignant disease within the past 5 years
- Autoimmune disease influencing thrombotic risk (e.g. inflammatory bowel disease, SLE, etc)
- Acute inflammation (including acute respiratory diseases, e.g. COVID-19, flu, RSV, etc)
- Current use of anticoagulants/antiplatelets including NSAIDs in the past 10 days
- Pregnancy or breastfeeding
- Chronic kidney/liver disase
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This proposal focuses on evaluating thrombin generation and thrombosis risk in women on different forms of hormonal contraceptives, with a particular emphasis on modifiable risk factors that influence thrombosis risk. The study aims to identify actionable predictors for VTE risk, paving the way for personalized risk assessment and management strategies.To assess thrombin generation profiles and prethrombotic state in women using different formulations of hormonal contraceptives.To compare thrombin generation parameters between HC users and non-users.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Evaluation of Thrombin Generation and Thrombosis Risk in Women on Hormonal Contraceptives with a Focus on Modifiable Risk Factors
- Plain-language title
- Blood clotting activity and clot risk in women using hormonal contraceptivesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from 2026-527084-15-00, who can take part
- Record updated
- 7 October 2026